{"ticker": {"uuid": "390d824b-1646-4982-88f9-bfe659de5d61", "symbol": "WHWK", "name": "Whitehawk Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest", "summary": "Whitehawk Therapeutics (NASDAQ:WHWK) experienced a substantial 139.9% increase in short interest during June, reaching 2.83 million shares. Despite this bearish sentiment, which represents 11.4% of the float and a 3.4-day days-to-cover ratio, analysts generally maintain a bullish", "url": "https://www.marketbeat.com/instant-alerts/whitehawk-therapeutics-inc-nasdaqwhwk-sees-large-increase-in-short-interest-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:11:22", "published_display": "14 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Whitehawk Therapeutics, Inc. \u2013 HAM:3350", "summary": "This article provides the title \"Price to book forward of Whitehawk Therapeutics, Inc. \u2013 HAM:3350\" but contains no substantive content beyond navigation and boilerplate website elements. It indicates the stock (HAM:3350) is listed on the Hamburg Stock Exchange and has no discerni", "url": "https://www.tradingview.com/symbols/HAM-3350/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T15:09:35", "published_display": "13 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners", "summary": "Leerink Partners initiated coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with an \"outperform\" rating and a $9.00 price target, suggesting a significant upside. The stock holds a \"Moderate Buy\" consensus among analysts with an average target price of $8.20. While the company re", "url": "https://www.marketbeat.com/instant-alerts/whitehawk-therapeutics-nasdaqwhwk-earns-outperform-rating-from-analysts-at-leerink-partners-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T13:09:35", "published_display": "13 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgJBVV95cUxNejBzbGRvSThWWkdCWmI3eHkzTjdzZ082OUtLYTEyeGJ6UzJDZHZsblBxUm5QUGxkM0wxYkhwQk1lRjdQblU1M0pMYldyU3BQUTF0dFowdzVwSDZjMndoR2d1TTB6T3pRNEtQaGhhdEVvbUtkazhVWmVGdE9XeUktZDhVWlozTXZvLXhJUmJVR29BSmVJVTUzWF9sWUh4MFNrUWlnVzNIakhBaDV1X1JzTXVoTjZxWmltcjFZRFY0TGRiNW9YZndRVV9idVFlaE1TR3BZYzVhdXdxbjBGcU9NTktTSjJpSEdOeDdSb052bmlyUWNKaTJIRTlFcnZIQmowRXJmeHFCdTUtdEdjOVFJaTBxa2NjdE1WM3ZCcHJIaTNUcHBQemYyYVNOcFlNMFkzMTFuY0l1dE4yNFljeFRTa2NR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T00:04:10+00:00", "published_display": "13 Jul 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development", "summary": "Biocytogen and Whitehawk Therapeutics announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Using Biocytogen's RenLite\u00ae platform for bispecific antibodies and Whitehawk's ADC linker-payload platform, they aim to create differentiated therapeutic", "url": "https://finance.yahoo.com/healthcare/articles/biocytogen-whitehawk-therapeutics-enter-global-120000794.html", "source_name": "Market source", "published_at": "2026-07-08T00:09:35", "published_display": "08 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WHWK - Whitehawk Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Whitehawk Therapeutics Inc. (WHWK), including its recent stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation ratios, profitability,", "url": "https://finviz.com/stock?t=WHWK&ta=1&p=d&ty=oc&b=2&ov=list_date", "source_name": "Finviz", "published_at": "2026-07-05T09:40:30", "published_display": "05 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WHWK - Whitehawk Therapeutics Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview of Whitehawk Therapeutics Inc (WHWK), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It covers the latest stock price, changes, market capitalization, earnings pe", "url": "https://finviz.com/stock?t=WHWK&p=m&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T01:41:00", "published_display": "04 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQSHhSZ1F4bzA3UlVDUUc1OFUyc2xWNGczZHBDOW1QYllqdmVDYlFSLWk0TjgtZTB2UTJTcDNDbXl0cE1kTDJneHFxLWhOUzRaQVNSaWFDMHBPTXZ1eXdRQmpudFI5elMydFY0N1ZTZk94RmdVamV2aVJZOGE4LWtVUFVuVE1EeTJIQ0ktdy0tUnY0ZEtsbnN3WldKTDNYYjFQT1lKR1k1ZFdSbWNGYVhucll4XzF5SW1wZGs5NHVfWTBqY3dhbWVoYjRqOEM?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "This page displays the \"Price to sales forward\" metric for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) on TradingView. The article is very sparse, showing only the company name, stock ticker, and the specific financial metric. It appears to be a stub or a data point within a larg", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:40:26", "published_display": "28 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. \u2013 FWB:3350", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Whitehawk Therapeutics, Inc. (FWB:3350), listed on the Frankfurt Stock Exchange. The content primarily shows financial data and market information provided by various financial services. It indicates that ", "url": "https://www.tradingview.com/symbols/FWB-3350/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:26", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "The article discusses the enterprise value to revenue forward for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of the company's financial information, news, and othe", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:40:21", "published_display": "27 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Whitehawk Therapeutics, Inc. \u2013 FWB:3350", "summary": "This article provides a brief overview of the \"Price to sales forward\" metric for Whitehawk Therapeutics, Inc. (FWB:3350) on the Frankfurt Stock Exchange. It lists the period, value, change, and percentage change. The content appears to be a financial data snippet from TradingVie", "url": "https://www.tradingview.com/symbols/FWB-3350/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:59", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics, Inc. Actuals & Estimates (NASDAQ:WHWK)", "summary": "This article provides an overview of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), including its current stock price, historical performance, and analyst forecasts. It details financial metrics, past earnings reports, upcoming earnings dates, and general information about the comp", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:42", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics, Inc. Actuals & Estimates (DUS:3350)", "summary": "This article provides an overview of Whitehawk Therapeutics, Inc. (DUS:3350), detailing its financial actuals and estimates as available on TradingView. It covers analyst forecasts, historical stock prices, recent earnings reports, revenue, net income, employee count, and EBITDA.", "url": "https://www.tradingview.com/symbols/DUS-3350/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T01:10:21", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "This page from TradingView provides financial information for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), specifically displaying its \"Price to earnings forward\" metric. The content indicates market status and links to various financial data, tools, and community features offere", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:10:18", "published_display": "25 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. \u2013 DUS:3350", "summary": "This article focuses on the enterprise value to revenue forward for Whitehawk Therapeutics, Inc. (DUS:3350), traded on the Dusseldorf Stock Exchange. It presents financial overview, news, community, forecasts, seasonals, and ETF information related to the company. The text is pri", "url": "https://www.tradingview.com/symbols/DUS-3350/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:52", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Whitehawk Therapeutics, Inc. \u2013 DUS:3350", "summary": "This article provides financial information for Whitehawk Therapeutics, Inc. (DUS:3350) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The market was closed at the time of publication, with no trades observed.", "url": "https://www.tradingview.com/symbols/DUS-3350/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:18", "published_display": "25 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B.Riley initiates Whitehawk Therapeutics stock rating at Buy on ADC portfolio", "summary": "B.Riley has initiated coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy rating and a price target of $10.00, citing the company's three-asset antibody-drug conjugate (ADC) portfolio. The stock is currently trading at $4.52, suggesting significant upside. Whitehawk Thera", "url": "https://ca.investing.com/news/stock-market-news/briley-initiates-whitehawk-therapeutics-stock-rating-at-buy-on-adc-portfolio-93CH-4707759", "source_name": "Investing.com Canada", "published_at": "2026-06-25T13:41:52", "published_display": "25 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Initiates Whitehawk Therapeutics at Buy With $10 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-initiates-whitehawk-therapeutics-114057073.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:40:57+00:00", "published_display": "25 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "This article provides financial information for Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) focusing on its enterprise value to EBIT forward ratio. It is presented in a data-centric format from TradingView, indicating no specific data points but rather a category for financial ana", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T11:41:52", "published_display": "25 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Inc. (WHWK) Q1 2026 Earnings: Narrower Loss Exceeds Estimates, Shares Climb - Net Profit Margin", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWklHOGJuTk5DdGRIRWZQcnhMMEdoUzdVUjl2VkZLc01aRkpfVVZUR1dQMnROb0NkTnFqRFdJVml2UTkyd25DcjFFZ1BSQnp2UmtsaFJ3Y0dVSnUzb0RoRG44dTVnbUwzWHpOQjhlSXZOcGhFSWNKak9uZUE5ZV9lQ3VmVEVMdjlwem9pdEFMNkxzRldxWkhtTGtzdmx6ZXBvZ1ZiaEh2SGdIQjFJX3hvZDljSTJONDRvQzFldVJqNWlIbUUtdnFVRW1LUFphX08zbmcyTHJUckp0MU0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16", "summary": "Whitehawk Therapeutics director Mohammad Hirmand was granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. These options will fully vest on the earlier of one year from the grant date or the day before the next annual stockholder meeti", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-df7c2dda166b.html", "source_name": "Stock Titan", "published_at": "2026-06-16T14:09:08", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director receives 38,040 stock options grant", "summary": "Whitehawk Therapeutics director Baiteng Zhao was granted 38,040 stock options as compensation, with an exercise price of $4.16 per share and an expiration date of June 12, 2036. The options will vest 100% after approximately one year or just before the next annual stockholder mee", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-5184a3f41e5f.html", "source_name": "Stock Titan", "published_at": "2026-06-16T13:39:53", "published_display": "16 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Richard Maroun receives 38,040 stock options at Whitehawk (WHWK)", "summary": "Whitehawk Therapeutics director Richard E. Maroun has been granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. The options will vest in a single tranche on the earlier of one year from the June 12, 2026 grant date or the day before t", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-c736e34f45f4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:40:24", "published_display": "16 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director receives 38,040 stock options at $4.16", "summary": "Whitehawk Therapeutics director Neil Desai was granted 38,040 stock options at an exercise price of $4.16 per share, expiring on June 12, 2036. The options vest 100% on the earlier of one year from the grant date or the day before the next annual stockholder meeting, contingent o", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-644cd98873f9.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:40:24", "published_display": "16 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk (WHWK) grants 38,040 stock options to director Aghazadeh", "summary": "Whitehawk Therapeutics, Inc. (WHWK) director and 10% owner Behzad Aghazadeh was granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. The options will vest in a single tranche on the earlier of one year from the grant date (June 12, 20", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-b5860d3d657e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:10:03", "published_display": "16 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director granted options on 38,040 shares", "summary": "Whitehawk Therapeutics director Caley Castelein has been granted stock options for 38,040 shares of the company's common stock, as disclosed in a recent Form 4 filing. The options have an exercise price of $4.16 per share and an expiration date of June 12, 2036. The shares will v", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-06ad8323e6b4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:10:03", "published_display": "16 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics shareholders elect directors and approve proposals at annual meeting", "summary": "Whitehawk Therapeutics (NASDAQ:WHWK) held its annual meeting, where shareholders elected three Class III directors, approved executive compensation on an advisory basis, and ratified the appointment of BDO USA, P.C. as their independent accounting firm. These decisions, based on ", "url": "https://www.investing.com/news/sec-filings/whitehawk-therapeutics-shareholders-elect-directors-and-approve-proposals-at-annual-meeting-93CH-4740820", "source_name": "Investing.com", "published_at": "2026-06-13T12:39:59", "published_display": "13 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders of Whitehawk Therapeutics (NASDAQ: WHWK) approve directors, pay and auditor", "summary": "Whitehawk Therapeutics (NASDAQ: WHWK) announced the results of its 2026 annual meeting of stockholders, where investors approved the election of three Class III directors, advisory compensation for named executive officers, and the ratification of BDO USA, P.C. as the independent", "url": "https://www.stocktitan.net/sec-filings/WHWK/8-k-whitehawk-therapeutics-inc-reports-material-event-7917ffd3b861.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:18", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?", "summary": "Whitehawk Therapeutics (WHWK) is highlighted as a hot biotech stock under $5, with a year-to-date gain of 71.49%. The company has been active with pipeline developments, including presenting real-world data for its ADC HWK-206 at ASCO 2026 and expanding its pipeline through an op", "url": "https://uk.finance.yahoo.com/news/whitehawk-therapeutics-whwk-one-hot-182255357.html", "source_name": "Market source", "published_at": "2026-06-10T18:22:00", "published_display": "10 Jun 2026 18:22", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Whitehawk Therapeutics, Inc. SEC Filing", "summary": "Whitehawk Therapeutics, Inc. (WHWK) has announced an SEC filing with a \"Notice of Effectiveness\" for its S-3 Shelf Registration, dated June 9, 2026, at 4:00 P.M. The filing impact and sentiment are noted as \"Neutral.\" The company's stock data and recent news, including presentati", "url": "https://www.stocktitan.net/sec-filings/WHWK/effect-whitehawk-therapeutics-inc-sec-filing-ba69e8cd8368.html", "source_name": "Stock Titan", "published_at": "2026-06-10T10:13:34", "published_display": "10 Jun 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Presents Real\u2011World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/whitehawk-therapeutics-presents-real-world-183000147.html", "source_name": "PR Newswire", "published_at": "2026-05-30T18:30:00+00:00", "published_display": "30 May 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/whitehawk-therapeutics-present-jefferies-2026-200500808.html", "source_name": "PR Newswire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/whitehawk-therapeutics-expands-adc-pipeline-210500491.html", "source_name": "PR Newswire", "published_at": "2026-05-21T21:05:00+00:00", "published_display": "21 May 2026 21:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit", "summary": "", "url": "https://finance.yahoo.com/news/whitehawk-therapeutics-participate-td-cowen-120000194.html", "source_name": "PR Newswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics: 'Hold' On Name Change, Next Generation PTK7 ADC Targeting (WHWK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQdzVjeDJYUTVUTzRhWWxMUVdGaUE3ME5xMEFiS29BWnJSS2M3V2RwYkk0UU9Xa2RoTVdacFRKQmdtaHNyVVZUYXhuNHdJUC1qOERpVVN1VzVSNFJoQkwyVVdSTkRMOGpCOTNtTUEyTGkzZTRWQVMzNkRaWF8zcTdRS3k0c0RaYW5xaV9qNVk1ajBUQlpEYUVVa0JEaGVzWVFQMlNDdGx3TnBPSFlXYXpfYzVyaHNfeUh5N24wTnNJbXBIY2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Whitehawk Therapeutics Raises $87.5 Million in PIPE, Selling Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNYi1qY2pCVmoxUVFvQk1ndDZJTTZfRnBSYmJzVmotc0YyWlBOLTRSVlJicmRXSnNwd1hyY2ZxYnNWeDBvbEhBUGg1eVZSN3RrY3Rsb2I4Nm1EYklIbE1PU2xCajhHTy00REZieDQ1Vkp5Qi1aaEc1dmRXSFNUUGZfak5jOHo0Mmo4RHZyUjRwVEYzaUFOZEpVWVA4Y3dVRlc5WU4tTUEwY2hxNHNHbUluTXB3TVdpS1JCNU1YZVFCRUcyNkpDRVBqUU1STWtDWm5UOHZHVGhkUkNxUG5qMG9wem1zN1E?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYXdTcmZNenB1dkcxWXYxVnpHNEJ5NXcyMGl4ejUzLXdpa0Y0dHdtS2Jac0hERjQ0d0xnRHVZOEM0V1lkdlNkQUYyRWdYaVhwSkdlQ1pHcnh4UTBRcVJhR3hkUDFjQ00zVEYtVndhZXlnNnVtQUVNSm9KZWJBanNuR0VsOHExcHU4X05sZk9LQ1ZCTzc2c0RMcVZsSjBNVk5KcENHeEVSWFljbHZkRHJuZUh2OUZHOGJFaWdweTgyZ0xVNzZ4WWFnTA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natural gas mineral firm WhiteHawk reveals sevenfold revenue surge in US IPO filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQb1NDbGtDclBkZEctcDlPb3pYQ3luY0hSUmpJQnNfbnBrQ0RNWTNYMkJxbWVfUkhmdlZDM05JVmZvZjJmT1dvZnRKcnJYQWFwRGVoLTRIZkRNbTF0UXl1M0pEWl9nbTY4SGtqOVFaZlN6NkkxRHd5QXdZNGU2SFRPeWhxZ3NwWEU3V19fUm9JNVNBMXR0RjRqbXNhR3pvNlBFbnJLR1NwTmM1Mjg?oc=5", "source_name": "Reuters", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cancer drug developer Whitehawk says $123M can fund operations into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOYWdTT2dTNDFyUzlmMDl6MGVCaXl6U1pQRDZrcVJPWDhHZEdGTkt2dC1CQ3BHcGVHejRaUEZ4YnJMMjJUejRPWnJueTB1TXF2VE1yVHFwV0c2X3kwWC1aMjZPcWFuMEJtdlYwSzBva05Wd0dGWVVmS0NmV3JMM2N3Umd4SGZEc19zWXBxMUpKWE55UDg0emU1eDBUd25LR1lVeVAtblNiOHFzLTBUWG05RnlKM1FYVG1aREdUUGpsYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Three Whitehawk cancer drug candidates shrank tumors at low doses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRHRRTUdRN1pZakhwUzFkZ01MQUVzclhycS0taTJCUU8tTmxoZmRwd0Z6UzBhV3paLVhEZGxQZTN3Qk5kejRkaTFFcDJ3ZHhXN2FmMk1YS0xEel91Z2xIb01maFhvR21PV3hTNU9jNkhuaVhlNUNFM1lPdVcyTmtzeTl3NFktNFJNaVMzZi1CdnQ4dEs4NWVqd1k3TEttM0JXMHFoWHRsVlY2OVlxTUNMeUYxSGxCUEh2?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQZG8tUXhuUXp4cmlwaFVCMVFYQmZDeldUcXZaZE1HRFZRSGZFN3doaTEtN0s1ekEzRXEySmc1b0ZvRG5EZkR2SnRTVkoyWXhLRk1DZ1RWV0VYbEtNc1ktRS1MR1c2ZDEwSHVTeXUtYk1YN2JUS1pUcXpMVHcyOUNsMEp4Ti1vMXZ4M0F2WEpuMVdlVDdKRzRCUXFDWGQzTVJJT0JnMlRpSVRKVHJlaG9mSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Shares Fly 27% But Investors Aren't Buying For Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WHWK Stock Price and Chart \u2014 NASDAQ:WHWK", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1RNzl4U3hYWDlzYUVRZEpxNG1kSGlDVVRpNVdNV3pLX1pLZVZkZXJIeVluYl9RaDhpaTBRRmNKVkZDUHZ4Q0haU1h0eXNpcDB6b1hFelNTeFhlV21l?oc=5", "source_name": "TradingView", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE93TkRZY0gtVFR3V3ZLakJJWnJOM1diaUJCaW8wRUdNalJabktXSTlQcFREejlhN2FkS01UcGxpSDR4WE53Y2VfVHFVVHpraXVJRkdj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:26:28+00:00", "published_display": "25 Apr 2025 03:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest", "summary": "Whitehawk Therapeutics (NASDAQ:WHWK) experienced a substantial 139.9% increase in short interest during June, reaching 2.83 million shares. Despite this bearish sentiment, which represents 11.4% of the float and a 3.4-day days-to-cover ratio, analysts generally maintain a bullish", "url": "https://www.marketbeat.com/instant-alerts/whitehawk-therapeutics-inc-nasdaqwhwk-sees-large-increase-in-short-interest-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:11:22", "published_display": "14 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Whitehawk Therapeutics, Inc. \u2013 HAM:3350", "summary": "This article provides the title \"Price to book forward of Whitehawk Therapeutics, Inc. \u2013 HAM:3350\" but contains no substantive content beyond navigation and boilerplate website elements. It indicates the stock (HAM:3350) is listed on the Hamburg Stock Exchange and has no discerni", "url": "https://www.tradingview.com/symbols/HAM-3350/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T15:09:35", "published_display": "13 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners", "summary": "Leerink Partners initiated coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with an \"outperform\" rating and a $9.00 price target, suggesting a significant upside. The stock holds a \"Moderate Buy\" consensus among analysts with an average target price of $8.20. While the company re", "url": "https://www.marketbeat.com/instant-alerts/whitehawk-therapeutics-nasdaqwhwk-earns-outperform-rating-from-analysts-at-leerink-partners-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T13:09:35", "published_display": "13 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgJBVV95cUxNejBzbGRvSThWWkdCWmI3eHkzTjdzZ082OUtLYTEyeGJ6UzJDZHZsblBxUm5QUGxkM0wxYkhwQk1lRjdQblU1M0pMYldyU3BQUTF0dFowdzVwSDZjMndoR2d1TTB6T3pRNEtQaGhhdEVvbUtkazhVWmVGdE9XeUktZDhVWlozTXZvLXhJUmJVR29BSmVJVTUzWF9sWUh4MFNrUWlnVzNIakhBaDV1X1JzTXVoTjZxWmltcjFZRFY0TGRiNW9YZndRVV9idVFlaE1TR3BZYzVhdXdxbjBGcU9NTktTSjJpSEdOeDdSb052bmlyUWNKaTJIRTlFcnZIQmowRXJmeHFCdTUtdEdjOVFJaTBxa2NjdE1WM3ZCcHJIaTNUcHBQemYyYVNOcFlNMFkzMTFuY0l1dE4yNFljeFRTa2NR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T00:04:10+00:00", "published_display": "13 Jul 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development", "summary": "Biocytogen and Whitehawk Therapeutics announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Using Biocytogen's RenLite\u00ae platform for bispecific antibodies and Whitehawk's ADC linker-payload platform, they aim to create differentiated therapeutic", "url": "https://finance.yahoo.com/healthcare/articles/biocytogen-whitehawk-therapeutics-enter-global-120000794.html", "source_name": "Market source", "published_at": "2026-07-08T00:09:35", "published_display": "08 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WHWK - Whitehawk Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Whitehawk Therapeutics Inc. (WHWK), including its recent stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation ratios, profitability,", "url": "https://finviz.com/stock?t=WHWK&ta=1&p=d&ty=oc&b=2&ov=list_date", "source_name": "Finviz", "published_at": "2026-07-05T09:40:30", "published_display": "05 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WHWK - Whitehawk Therapeutics Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview of Whitehawk Therapeutics Inc (WHWK), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It covers the latest stock price, changes, market capitalization, earnings pe", "url": "https://finviz.com/stock?t=WHWK&p=m&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T01:41:00", "published_display": "04 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQSHhSZ1F4bzA3UlVDUUc1OFUyc2xWNGczZHBDOW1QYllqdmVDYlFSLWk0TjgtZTB2UTJTcDNDbXl0cE1kTDJneHFxLWhOUzRaQVNSaWFDMHBPTXZ1eXdRQmpudFI5elMydFY0N1ZTZk94RmdVamV2aVJZOGE4LWtVUFVuVE1EeTJIQ0ktdy0tUnY0ZEtsbnN3WldKTDNYYjFQT1lKR1k1ZFdSbWNGYVhucll4XzF5SW1wZGs5NHVfWTBqY3dhbWVoYjRqOEM?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "This page displays the \"Price to sales forward\" metric for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) on TradingView. The article is very sparse, showing only the company name, stock ticker, and the specific financial metric. It appears to be a stub or a data point within a larg", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:40:26", "published_display": "28 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. \u2013 FWB:3350", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Whitehawk Therapeutics, Inc. (FWB:3350), listed on the Frankfurt Stock Exchange. The content primarily shows financial data and market information provided by various financial services. It indicates that ", "url": "https://www.tradingview.com/symbols/FWB-3350/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:26", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "The article discusses the enterprise value to revenue forward for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of the company's financial information, news, and othe", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:40:21", "published_display": "27 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Whitehawk Therapeutics, Inc. \u2013 FWB:3350", "summary": "This article provides a brief overview of the \"Price to sales forward\" metric for Whitehawk Therapeutics, Inc. (FWB:3350) on the Frankfurt Stock Exchange. It lists the period, value, change, and percentage change. The content appears to be a financial data snippet from TradingVie", "url": "https://www.tradingview.com/symbols/FWB-3350/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:59", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics, Inc. Actuals & Estimates (NASDAQ:WHWK)", "summary": "This article provides an overview of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), including its current stock price, historical performance, and analyst forecasts. It details financial metrics, past earnings reports, upcoming earnings dates, and general information about the comp", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:42", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics, Inc. Actuals & Estimates (DUS:3350)", "summary": "This article provides an overview of Whitehawk Therapeutics, Inc. (DUS:3350), detailing its financial actuals and estimates as available on TradingView. It covers analyst forecasts, historical stock prices, recent earnings reports, revenue, net income, employee count, and EBITDA.", "url": "https://www.tradingview.com/symbols/DUS-3350/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T01:10:21", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "This page from TradingView provides financial information for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), specifically displaying its \"Price to earnings forward\" metric. The content indicates market status and links to various financial data, tools, and community features offere", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:10:18", "published_display": "25 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. \u2013 DUS:3350", "summary": "This article focuses on the enterprise value to revenue forward for Whitehawk Therapeutics, Inc. (DUS:3350), traded on the Dusseldorf Stock Exchange. It presents financial overview, news, community, forecasts, seasonals, and ETF information related to the company. The text is pri", "url": "https://www.tradingview.com/symbols/DUS-3350/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:52", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Whitehawk Therapeutics, Inc. \u2013 DUS:3350", "summary": "This article provides financial information for Whitehawk Therapeutics, Inc. (DUS:3350) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The market was closed at the time of publication, with no trades observed.", "url": "https://www.tradingview.com/symbols/DUS-3350/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:18", "published_display": "25 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B.Riley initiates Whitehawk Therapeutics stock rating at Buy on ADC portfolio", "summary": "B.Riley has initiated coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy rating and a price target of $10.00, citing the company's three-asset antibody-drug conjugate (ADC) portfolio. The stock is currently trading at $4.52, suggesting significant upside. Whitehawk Thera", "url": "https://ca.investing.com/news/stock-market-news/briley-initiates-whitehawk-therapeutics-stock-rating-at-buy-on-adc-portfolio-93CH-4707759", "source_name": "Investing.com Canada", "published_at": "2026-06-25T13:41:52", "published_display": "25 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Initiates Whitehawk Therapeutics at Buy With $10 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-initiates-whitehawk-therapeutics-114057073.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:40:57+00:00", "published_display": "25 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Whitehawk Therapeutics, Inc. \u2013 NASDAQ:WHWK", "summary": "This article provides financial information for Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) focusing on its enterprise value to EBIT forward ratio. It is presented in a data-centric format from TradingView, indicating no specific data points but rather a category for financial ana", "url": "https://www.tradingview.com/symbols/NASDAQ-WHWK/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T11:41:52", "published_display": "25 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Inc. (WHWK) Q1 2026 Earnings: Narrower Loss Exceeds Estimates, Shares Climb - Net Profit Margin", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWklHOGJuTk5DdGRIRWZQcnhMMEdoUzdVUjl2VkZLc01aRkpfVVZUR1dQMnROb0NkTnFqRFdJVml2UTkyd25DcjFFZ1BSQnp2UmtsaFJ3Y0dVSnUzb0RoRG44dTVnbUwzWHpOQjhlSXZOcGhFSWNKak9uZUE5ZV9lQ3VmVEVMdjlwem9pdEFMNkxzRldxWkhtTGtzdmx6ZXBvZ1ZiaEh2SGdIQjFJX3hvZDljSTJONDRvQzFldVJqNWlIbUUtdnFVRW1LUFphX08zbmcyTHJUckp0MU0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16", "summary": "Whitehawk Therapeutics director Mohammad Hirmand was granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. These options will fully vest on the earlier of one year from the grant date or the day before the next annual stockholder meeti", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-df7c2dda166b.html", "source_name": "Stock Titan", "published_at": "2026-06-16T14:09:08", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director receives 38,040 stock options grant", "summary": "Whitehawk Therapeutics director Baiteng Zhao was granted 38,040 stock options as compensation, with an exercise price of $4.16 per share and an expiration date of June 12, 2036. The options will vest 100% after approximately one year or just before the next annual stockholder mee", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-5184a3f41e5f.html", "source_name": "Stock Titan", "published_at": "2026-06-16T13:39:53", "published_display": "16 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Richard Maroun receives 38,040 stock options at Whitehawk (WHWK)", "summary": "Whitehawk Therapeutics director Richard E. Maroun has been granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. The options will vest in a single tranche on the earlier of one year from the June 12, 2026 grant date or the day before t", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-c736e34f45f4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:40:24", "published_display": "16 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director receives 38,040 stock options at $4.16", "summary": "Whitehawk Therapeutics director Neil Desai was granted 38,040 stock options at an exercise price of $4.16 per share, expiring on June 12, 2036. The options vest 100% on the earlier of one year from the grant date or the day before the next annual stockholder meeting, contingent o", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-644cd98873f9.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:40:24", "published_display": "16 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk (WHWK) grants 38,040 stock options to director Aghazadeh", "summary": "Whitehawk Therapeutics, Inc. (WHWK) director and 10% owner Behzad Aghazadeh was granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. The options will vest in a single tranche on the earlier of one year from the grant date (June 12, 20", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-b5860d3d657e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:10:03", "published_display": "16 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) director granted options on 38,040 shares", "summary": "Whitehawk Therapeutics director Caley Castelein has been granted stock options for 38,040 shares of the company's common stock, as disclosed in a recent Form 4 filing. The options have an exercise price of $4.16 per share and an expiration date of June 12, 2036. The shares will v", "url": "https://www.stocktitan.net/sec-filings/WHWK/form-4-whitehawk-therapeutics-inc-insider-trading-activity-06ad8323e6b4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T01:10:03", "published_display": "16 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics shareholders elect directors and approve proposals at annual meeting", "summary": "Whitehawk Therapeutics (NASDAQ:WHWK) held its annual meeting, where shareholders elected three Class III directors, approved executive compensation on an advisory basis, and ratified the appointment of BDO USA, P.C. as their independent accounting firm. These decisions, based on ", "url": "https://www.investing.com/news/sec-filings/whitehawk-therapeutics-shareholders-elect-directors-and-approve-proposals-at-annual-meeting-93CH-4740820", "source_name": "Investing.com", "published_at": "2026-06-13T12:39:59", "published_display": "13 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders of Whitehawk Therapeutics (NASDAQ: WHWK) approve directors, pay and auditor", "summary": "Whitehawk Therapeutics (NASDAQ: WHWK) announced the results of its 2026 annual meeting of stockholders, where investors approved the election of three Class III directors, advisory compensation for named executive officers, and the ratification of BDO USA, P.C. as the independent", "url": "https://www.stocktitan.net/sec-filings/WHWK/8-k-whitehawk-therapeutics-inc-reports-material-event-7917ffd3b861.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:18", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?", "summary": "Whitehawk Therapeutics (WHWK) is highlighted as a hot biotech stock under $5, with a year-to-date gain of 71.49%. The company has been active with pipeline developments, including presenting real-world data for its ADC HWK-206 at ASCO 2026 and expanding its pipeline through an op", "url": "https://uk.finance.yahoo.com/news/whitehawk-therapeutics-whwk-one-hot-182255357.html", "source_name": "Market source", "published_at": "2026-06-10T18:22:00", "published_display": "10 Jun 2026 18:22", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Whitehawk Therapeutics, Inc. SEC Filing", "summary": "Whitehawk Therapeutics, Inc. (WHWK) has announced an SEC filing with a \"Notice of Effectiveness\" for its S-3 Shelf Registration, dated June 9, 2026, at 4:00 P.M. The filing impact and sentiment are noted as \"Neutral.\" The company's stock data and recent news, including presentati", "url": "https://www.stocktitan.net/sec-filings/WHWK/effect-whitehawk-therapeutics-inc-sec-filing-ba69e8cd8368.html", "source_name": "Stock Titan", "published_at": "2026-06-10T10:13:34", "published_display": "10 Jun 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Presents Real\u2011World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/whitehawk-therapeutics-presents-real-world-183000147.html", "source_name": "PR Newswire", "published_at": "2026-05-30T18:30:00+00:00", "published_display": "30 May 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/whitehawk-therapeutics-present-jefferies-2026-200500808.html", "source_name": "PR Newswire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/whitehawk-therapeutics-expands-adc-pipeline-210500491.html", "source_name": "PR Newswire", "published_at": "2026-05-21T21:05:00+00:00", "published_display": "21 May 2026 21:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit", "summary": "", "url": "https://finance.yahoo.com/news/whitehawk-therapeutics-participate-td-cowen-120000194.html", "source_name": "PR Newswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics: 'Hold' On Name Change, Next Generation PTK7 ADC Targeting (WHWK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQdzVjeDJYUTVUTzRhWWxMUVdGaUE3ME5xMEFiS29BWnJSS2M3V2RwYkk0UU9Xa2RoTVdacFRKQmdtaHNyVVZUYXhuNHdJUC1qOERpVVN1VzVSNFJoQkwyVVdSTkRMOGpCOTNtTUEyTGkzZTRWQVMzNkRaWF8zcTdRS3k0c0RaYW5xaV9qNVk1ajBUQlpEYUVVa0JEaGVzWVFQMlNDdGx3TnBPSFlXYXpfYzVyaHNfeUh5N24wTnNJbXBIY2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Raises $87.5 Million in PIPE, Selling Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNYi1qY2pCVmoxUVFvQk1ndDZJTTZfRnBSYmJzVmotc0YyWlBOLTRSVlJicmRXSnNwd1hyY2ZxYnNWeDBvbEhBUGg1eVZSN3RrY3Rsb2I4Nm1EYklIbE1PU2xCajhHTy00REZieDQ1Vkp5Qi1aaEc1dmRXSFNUUGZfak5jOHo0Mmo4RHZyUjRwVEYzaUFOZEpVWVA4Y3dVRlc5WU4tTUEwY2hxNHNHbUluTXB3TVdpS1JCNU1YZVFCRUcyNkpDRVBqUU1STWtDWm5UOHZHVGhkUkNxUG5qMG9wem1zN1E?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYXdTcmZNenB1dkcxWXYxVnpHNEJ5NXcyMGl4ejUzLXdpa0Y0dHdtS2Jac0hERjQ0d0xnRHVZOEM0V1lkdlNkQUYyRWdYaVhwSkdlQ1pHcnh4UTBRcVJhR3hkUDFjQ00zVEYtVndhZXlnNnVtQUVNSm9KZWJBanNuR0VsOHExcHU4X05sZk9LQ1ZCTzc2c0RMcVZsSjBNVk5KcENHeEVSWFljbHZkRHJuZUh2OUZHOGJFaWdweTgyZ0xVNzZ4WWFnTA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natural gas mineral firm WhiteHawk reveals sevenfold revenue surge in US IPO filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQb1NDbGtDclBkZEctcDlPb3pYQ3luY0hSUmpJQnNfbnBrQ0RNWTNYMkJxbWVfUkhmdlZDM05JVmZvZjJmT1dvZnRKcnJYQWFwRGVoLTRIZkRNbTF0UXl1M0pEWl9nbTY4SGtqOVFaZlN6NkkxRHd5QXdZNGU2SFRPeWhxZ3NwWEU3V19fUm9JNVNBMXR0RjRqbXNhR3pvNlBFbnJLR1NwTmM1Mjg?oc=5", "source_name": "Reuters", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug developer Whitehawk says $123M can fund operations into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOYWdTT2dTNDFyUzlmMDl6MGVCaXl6U1pQRDZrcVJPWDhHZEdGTkt2dC1CQ3BHcGVHejRaUEZ4YnJMMjJUejRPWnJueTB1TXF2VE1yVHFwV0c2X3kwWC1aMjZPcWFuMEJtdlYwSzBva05Wd0dGWVVmS0NmV3JMM2N3Umd4SGZEc19zWXBxMUpKWE55UDg0emU1eDBUd25LR1lVeVAtblNiOHFzLTBUWG05RnlKM1FYVG1aREdUUGpsYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three Whitehawk cancer drug candidates shrank tumors at low doses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRHRRTUdRN1pZakhwUzFkZ01MQUVzclhycS0taTJCUU8tTmxoZmRwd0Z6UzBhV3paLVhEZGxQZTN3Qk5kejRkaTFFcDJ3ZHhXN2FmMk1YS0xEel91Z2xIb01maFhvR21PV3hTNU9jNkhuaVhlNUNFM1lPdVcyTmtzeTl3NFktNFJNaVMzZi1CdnQ4dEs4NWVqd1k3TEttM0JXMHFoWHRsVlY2OVlxTUNMeUYxSGxCUEh2?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQZG8tUXhuUXp4cmlwaFVCMVFYQmZDeldUcXZaZE1HRFZRSGZFN3doaTEtN0s1ekEzRXEySmc1b0ZvRG5EZkR2SnRTVkoyWXhLRk1DZ1RWV0VYbEtNc1ktRS1MR1c2ZDEwSHVTeXUtYk1YN2JUS1pUcXpMVHcyOUNsMEp4Ti1vMXZ4M0F2WEpuMVdlVDdKRzRCUXFDWGQzTVJJT0JnMlRpSVRKVHJlaG9mSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Shares Fly 27% But Investors Aren't Buying For Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WHWK Stock Price and Chart \u2014 NASDAQ:WHWK", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1RNzl4U3hYWDlzYUVRZEpxNG1kSGlDVVRpNVdNV3pLX1pLZVZkZXJIeVluYl9RaDhpaTBRRmNKVkZDUHZ4Q0haU1h0eXNpcDB6b1hFelNTeFhlV21l?oc=5", "source_name": "TradingView", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE93TkRZY0gtVFR3V3ZLakJJWnJOM1diaUJCaW8wRUdNalJabktXSTlQcFREejlhN2FkS01UcGxpSDR4WE53Y2VfVHFVVHpraXVJRkdj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:26:28+00:00", "published_display": "25 Apr 2025 03:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 53, "sentiment_summary": {"positive": 12, "negative": 3, "neutral": 38, "score": 53, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 16.85, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}], "positive_events": 12, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 3.97, "latest_week": "2026-07-10", "one_week_move": -5.3, "four_week_move": -4.6, "twelve_week_move": -3.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.135612, "market_dynamics_buy_signal": false, "relative_strength": 18.789966, "fair_value_gap": 44.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.8887, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.3% over one week, -4.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 14}, {"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 8}, {"label": "PR Newswire", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "MarketBeat", "count": 2}, {"label": "Finviz", "count": 2}, {"label": "Moomoo", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 5}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.3% over one week, -4.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest"}], "updated_at": "2026-07-16T08:52:16.126554+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}